Ann Intern Med
Shorter antibiotic courses may be enough for some hospitalized pneumonia patients
Clinical takeaway: For a carefully selected minority of hospitalized adults with community-acquired pneumonia (CAP) who stabilize early, reassessing antibiotic duration at day 3–4 may safely reduce overall exposure and related harms while maintaining clinical outcomes.
Standard practice has long favored antibiotic courses of at least 5 days for hospitalized CAP, even though prior trials suggest shorter durations may be safe once patients reach early clinical stability—leaving uncertainty about how often this can be applied in real‑world care.
In a multicenter target trial emulation, investigators examined whether brief antibiotic courses are safe for adults hospitalized with CAP who achieve early clinical stability. Using data from 67 Michigan hospitals (2017–2024), researchers compared patients treated for 3 to 4 days with those receiving ≥5 days of antibiotics. Only about 10% of hospitalized CAP patients met strict eligibility criteria for short-course therapy, underscoring how selective this approach must be.
Among eligible patients, outcomes were similar between groups. There were no meaningful differences in mortality, hospital readmissions, urgent care visits, or C. difficile infection rates through follow-up. These findings suggest shorter treatment durations can be effective when patients demonstrate rapid clinical improvement.
The authors emphasized that patient selection is key and cautioned that the relatively small number of short-course cases limits definitive conclusions. Still, the results align with growing evidence that “less can be more” when antibiotics are tailored to clinical response rather than fixed durations.
Source: Doumat G, et al. (2026, April 14). Ann Intern Med. Short Versus Longer Antibiotic Duration for Community‑Acquired Pneumonia: A Multicenter Target Trial Emulation